Cargando…

Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis

BACKGROUND AND OBJECTIVE: Nearly 10 % of all US hospital admissions are attributed to acute bacterial skin and skin structure infections (ABSSSIs). While most antibacterials used to treat these infections require multi-day and multi-dose regimens, a single-dose treatment is now available. The object...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jensen, Ivar S., Lodise, Thomas P., Fan, Weihong, Wu, Chining, Cyr, Philip L., Nicolau, David P, DuFour, Scott, Sulham, Katherine A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740574/ https://www.ncbi.nlm.nih.gov/pubmed/26692006 http://dx.doi.org/10.1007/s40261-015-0365-8

Ejemplares similares

Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis
por: Jensen, Ivar S., et al.
Publicado: (2016)

Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials
por: Lodise, Thomas P., et al.
Publicado: (2017)

Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
por: Deck, Daniel H., et al.
Publicado: (2016)

Erratum to: Single-Dose Oritavancin Treatment of Acute Bacterial Skin and Skin Structure Infections: SOLO Trial Efficacy by Eron Severity and Management Setting
por: Deck, Daniel H., et al.
Publicado: (2016)

Expediting Discharge in Hospitalized, Adult Patients with Skin and Soft Tissue Infections Who Received Empiric Vancomycin Therapy with Oritavancin: Description of Findings from an Institutional Pathway
por: Whittaker, Cristen, et al.
Publicado: (2020)

Single-Dose Oritavancin Compared to Standard of Care IV Antibiotics for Acute Bacterial Skin and Skin Structure Infection in the Outpatient Setting: A Retrospective Real-World Study
por: Anastasio, Patrick J., et al.
Publicado: (2017)

Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review
por: Kmeid, Joumana, et al.
Publicado: (2015)

The Real-World Economic and Clinical Management of Adult Patients with Skin and Soft Tissue Infections (SSTIs) with Oritavancin: Data from Two Multicenter Observational Cohort Studies
por: Estrada, Sandy, et al.
Publicado: (2020)

Early Directed Oritavancin Therapy in the Emergency Department May Lead to Hospital Avoidance Compared to Standard Treatment for Acute Bacterial Skin and Skin Structure Infections: A Real-World Retrospective Analysis
por: Helton, Brittany, et al.
Publicado: (2020)

Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin or Vancomycin for a Skin Infection in the Outpatient Setting
por: Lodise, Thomas P, et al.
Publicado: (2019)

Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections
por: Mitra, Subhashis, et al.
Publicado: (2015)

Evaluation of Dalbavancin and Oritavancin as Cost-Effective Treatments of Acute Bacterial Skin and Skin Structure Infections in Hospitalized Patients
por: Koutsari, Christina, et al.
Publicado: (2017)

1928. Comparisons of 30-Day Admission and 30-Day Total Healthcare Costs Between Patients Who Were Treated With Oritavancin (ORI) or Vancomycin (VAN) for a Skin Infection in the Outpatient Setting
por: Lodise, Thomas, et al.
Publicado: (2018)

288. Expediting Discharge in Acute Bacterial Skin and Skin Structure Infections: A Clinical and Economic Comparison Between Vancomycin and Oritavancin
por: Whittaker, Cristen, et al.
Publicado: (2018)

447. Disease Progression in Patients with Acute Bacterial Skin and Skin Structure Infections: A Comparative Analysis Between Oritavancin and Vancomycin
por: Whittaker, Cristen A, et al.
Publicado: (2019)

Cost-minimisation analysis of oritavancin for the treatment of acute bacterial skin and skin structure infections from a United Kingdom perspective
por: Zinzi, Daniela, et al.
Publicado: (2022)

1812. Comparative Activity of Oritavancin and Comparator Agents against Staphylococcus aureus and Streptococcus spp. Causing Skin and Skin Structure Infections in US Medical Centers between 2017–2019 and 2022
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections
por: Brade, Karrine D., et al.
Publicado: (2016)

1439. Epidemiology and 12- Month Antibiotic Use in the Outpatient Setting among Adult Patients with Complicated Urinary Tract Infections: A Retrospective Database Analysis
por: Lodise, Thomas, et al.
Publicado: (2021)

470 Oritavancin Activity Against Gram-positive Clinical Isolates Responsible for Documented Skin and Skin Structure Infections in USA and European Hospitals (2012-2013)
por: Mendes, Rodrigo E., et al.
Publicado: (2014)

Improved economic and clinical outcomes with oritavancin versus a comparator group for treatment of acute bacterial skin and skin structure infections in a community hospital
por: Saddler, Kimberly, et al.
Publicado: (2021)

1673. Epidemiology of Complicated Urinary Tract Infections (cUTIs) Presenting in Emergency Departments Across the United States (US)
por: Lodise, Thomas, et al.
Publicado: (2020)

1811. Impact of a one-time oritavancin infusion on hospital length of stay for uncomplicated skin and soft tissue infections
por: Bremmer, Derek N, et al.
Publicado: (2023)

1683. Hospital Admission Patterns in Adult Patients with Complicated Urinary Tract Infections (cUTIs): Identification of Potentially Avoidable Hospital Admissions Across United States (US) Hospitals
por: Lodise, Thomas, et al.
Publicado: (2020)

1331 The SOLO Studies: A Single-Dose of Oritavancin (ORI) Compared to 7-10 Days of Vancomycin (VAN) in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Corey, Ralph, et al.
Publicado: (2014)

Use of oral tetracyclines in the treatment of adult outpatients with skin and skin structure infections: Focus on doxycycline, minocycline, and omadacycline
por: Bidell, Monique R., et al.
Publicado: (2021)

Real-World Use of Oritavancin for the Treatment of Osteomyelitis
por: Scoble, Patrick J., et al.
Publicado: (2020)

Activity of Oritavancin and Its Synergy with Other Antibiotics against Mycobacterium abscessus Infection In Vitro and In Vivo
por: Wang, Gaoyan, et al.
Publicado: (2021)

Vibrational Optical Activity Study of Four Antibiotic (Lipo)glycopeptides: Vancomycin, Oritavancin, Dalbavancin, and Teicoplanin
por: Aerts, Roy, et al.
Publicado: (2022)

A Retrospective Cohort Analysis Shows that Coadministration of Minocycline with Colistin in Critically Ill Patients Is Associated with Reduced Frequency of Acute Renal Failure
por: Lodise, Thomas P., et al.
Publicado: (2017)

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
por: Bradley, John, et al.
Publicado: (2018)

The Clinical Efficacy of Multidose Oritavancin: A Systematic Review
por: Baiardi, Giammarco, et al.
Publicado: (2023)

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

Oritavancin polymethylmethacrylate (PMMA)—compressive strength testing and in vitro elution
por: Schmidt-Malan, Suzannah M., et al.
Publicado: (2019)

Real-World Evidence for Oritavancin Use in Gram-Positive Infections
Publicado: (2020)

Distinct Effectiveness of Oritavancin against Tolerance-Induced Staphylococcus aureus
por: Berti, Andrew D., et al.
Publicado: (2020)

1420. Successful Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties
por: Hoover, Randall K, et al.
Publicado: (2022)

439. Iclaprim Use for Acute Bacterial Skin and Skin Structure Infection (ABSSSI) is Not Associated with Hyperkalemia: Phase 3 REVIVE Studies
por: Huang, David B, et al.
Publicado: (2019)

Acute Bacterial Skin and Skin Structure Infections Treated with Intravenous Antibiotics in the Emergency Department or Observational Unit: Experience at the Detroit Medical Center
por: Claeys, Kimberly C., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_augn5oohkgkdd8pq6vtq8j56p9